Pharmaceuticals

Drug Development Drug Pricing Drug Approval Clinical Trials Drug Safety Weight Loss Drugs Biotechnology Prescription Drugs Drug Regulation Prescription Medications

Eli Lilly Trades Near $1,160 as GLP-1 Sales and FDA Cardio Approval Drive Valuation

Investors are debating whether future returns will come from continued drug performance and pipeline wins rather than a cosmetic stock split.

Medsafe Authorises Two Psychiatrists to Deliver MDMA Therapy for Severe PTSD

FDA Works With Manufacturers to Expand Supply of Estradiol Menopause Patches

FDA Approves Zanvastro as First Treatment for Alexander Disease

Teva’s Experimental Antibody Prevents Gluten‑Triggered Intestinal Damage in Mid‑Stage Celiac Trial

Trump Adds Nine Drugmakers to Most‑Favored‑Nation Pricing Program

McKesson Confirms Cloud Data Theft by Extortion Group

Judge Pauses Texas-Florida Mifepristone Lawsuit Pending FDA Review

Florida Sues Prime Therapeutics and Express Scripts Over Alleged PBM Price‑Fixing

Engineered Suppressor tRNAs Delivered by Inhaled Nanoparticles Restore CFTR Function in Preclinical Models

Moderna’s Phase 3 Melanoma Win Reprices the Company

McKesson Agrees to Buy Precision Medicine Group for About $2.25 Billion

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

Lilly Sues Six U.S. Sellers Over Black‑Market Sales of Unapproved Retatrutide

U.S. Drug Prices Fall at Fastest Pace in 63 Years, CMS Says

Clear Eyes Recalls Nearly 40,000 Bottles Over Sterility Concerns

J&J Raises Guidance as Thermo Fisher Shows Early Lab‑Spending Recovery

GLP-1 Drugs Reshape Obesity Care

U.S. Prescription Drug Prices Drop 3.1% Year Over Year

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug